NCT03278782 2026-01-09
Study of Pembrolizumab (MK-3475) in Combination With Romidepsin
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
M.D. Anderson Cancer Center
Mayo Clinic
National Cancer Institute (NCI)
Ohio State University Comprehensive Cancer Center